SAN DIEGO, July 21, 2014 /PRNewswire/ -- Agena Bioscience, Inc., the provider of the MassARRAY® System for genetic analysis, announced today that Peter Dansky has joined the company as its Chief Executive Officer and as a member of the Board of Directors. Dansky, the former President of the Molecular & Cell Biology Division of Life Technologies, will lead Agena's expansion of its genetic analysis business into new application areas including clinical diagnostics.
"We are delighted that Peter has joined Agena Bioscience to lead the company through its next phase of growth. Agena's powerful and efficient MassARRAY technology has gained worldwide adoption in the genetic research analysis arena and Peter's experience in building life science companies will be invaluable as our company expands into new application areas," stated John Lillig, Agena Bioscience's Chairman. "With the recent FDA approval of Agena's IMPACT Dx System as a foundation, Peter will direct the company's initiatives to deploy its highly sensitive, cost effective platform for genetic analysis into clinical research and diagnostics applications. Peter's knowledge of the life sciences and clinical markets, coupled with his strategic and operational expertise, will enable him to guide the highly talented team at Agena into areas of expanded commercial growth."
Dansky holds an M.B.A. from Boston College and a M.S. and B.S. in Chemical Engineering from Tufts University. He previously served as President of the Molecular Biology Systems Division at Life Technologies and was also President of the Functional Analysis Division at Applied Biosystems. He has 30 years of leadership experience in strategic business development, marketing, product development, sales, operations and general management from a variety of market leading life science companies, including Arcturus Bioscience, Affymetrix, Molecular Dynamics, PerSeptive BioSystems and Millipore.
"I am excited to join Agena Bioscience at this pivotal stage of its development. The company has the potential to become a leading research and diagnostics platform provider and its technology has excellent growth opportunities in many related life science application areas," said Dansky. "MassARRAY and IMPACT Dx provide the broad platform capabilities necessary for highly multiplexed, sensitive and cost effective genetic profiling. Through the hard work of the Agena Bioscience team and its customers, MassARRAY has developed a strong reputation in the research community and we look forward to leveraging these advancements into new global markets and into the clinical diagnostics industry."
About Agena Bioscience
Agena Bioscience is a San Diego, CA, based life sciences and clinical diagnostics company that offers the MassARRAY® and IMPACT Dx Systems. These systems incorporate a highly sensitive, quantitative method for nucleic acid detection via MALDI-TOF mass spectrometry for high-throughput genotyping and mutation profiling for cancer and other disease research, companion diagnostics, pharmacogenomics, epigenetics, clinical genetics, ag-bio genetics, blood banking sample characterization, and biobanking molecular sample identification. www.agenabio.com
SOURCE Agena Bioscience, Inc.